These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37072108)

  • 1. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
    Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
    Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
    Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
    J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2018 Aug; 28(8):976-981. PubMed ID: 29848239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
    Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
    Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK
    World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
    Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
    Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recovery rate in differentiated thyroid cancer. Experiences of one of the Hungarian clinical centers].
    Szujó S; Bajnok L; Bódis B; Nemes O; Rucz K; Mezősi E
    Orv Hetil; 2018 Jun; 159(22):878-884. PubMed ID: 29806478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years.
    Gemsenjäger E; Heitz PU; Seifert B; Martina B; Schweizer I
    Swiss Med Wkly; 2001 Mar; 131(11-12):157-63. PubMed ID: 11416889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
    Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
    Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
    Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
    Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.